Literature DB >> 15529338

Global proteomic approach unmasks involvement of keratins 8 and 18 in the delivery of cystic fibrosis transmembrane conductance regulator (CFTR)/deltaF508-CFTR to the plasma membrane.

Noélie Davezac1, Danielle Tondelier, Joanna Lipecka, Pascale Fanen, France Demaugre, Janusz Debski, Michal Dadlez, André Schrattenholz, Michael A Cahill, Aleksander Edelman.   

Abstract

Cystic fibrosis (CF) is a genetic disease caused by mutations in the CF gene (cftr). Physiologically, CF is characterized by an abnormal chloride secretion in epithelia due to a dysfunction of a mutated cystic fibrosis transmembrane conductance regulator (CFTR). CFTR is a cAMP-dependent chloride channel whose most frequent mutation, deltaF508, leads to an aberrantly folded protein which causes a dysfunction of the channel. However, a growing number of reports suggest that modifier genes and environmental factors are involved in the physiology of CF. To identify proteins whose expression depends on wild-type WT-CFTR or deltaF508-CFTR, we chose a global proteomic approach based on the use of two-dimensional gel electrophoresis (2-DE) and mass spectrometry. The experiments were carried out with HeLa cells stably transfected with WT-CFTR (pTCFWT) or deltaF508-CFTR (pTCFdeltaF508). These experiments unmasked keratin 8 (K8) and 18 (K18) which were differentially expressed in pTCFWT vs. pTCFdeltaF508. An immunoblot of K18 confirmed the 2-DE results. Intracellular localization experiments of WT-CFTR, deltaF508-CFTR, K8, and K18 suggest that the expression of these proteins are linked, and that the concentrations of K8 and K18 and/or their distribution may be involved in the traffic of WT-CFTR/deltaF508-CFTR. A functional assay for CFTR revealed that specifically lowering K18 expression or changing its distribution leads to the delivery of functional deltaF508-CFTR to the plasma membrane. This work suggests a novel function of K18 in CF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15529338     DOI: 10.1002/pmic.200400850

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  16 in total

1.  Finding new drugs to enhance anion secretion in cystic fibrosis: Toward suitable systems for better drug screening. Report on the pre-conference meeting to the 12th ECFS Basic Science Conference, Albufeira, 25-28 March 2015.

Authors:  Alan S Verkman; Aleksander Edelman; Margarida Amaral; Marcus A Mall; Jeffrey M Beekman; Torsten Meiners; Luis J V Galietta; Christine E Bear
Journal:  J Cyst Fibros       Date:  2015-10-21       Impact factor: 5.482

2.  Disruption of cytokeratin-8 interaction with F508del-CFTR corrects its functional defect.

Authors:  Julien Colas; Grazyna Faure; Emilie Saussereau; Stéphanie Trudel; Wael M Rabeh; Sara Bitam; Ida Chiara Guerrera; Janine Fritsch; Isabelle Sermet-Gaudelus; Noëlie Davezac; Franck Brouillard; Gergely L Lukacs; Harald Herrmann; Mario Ollero; Aleksander Edelman
Journal:  Hum Mol Genet       Date:  2011-10-28       Impact factor: 6.150

3.  New insights into interactions between the nucleotide-binding domain of CFTR and keratin 8.

Authors:  Aiswarya Premchandar; Anna Kupniewska; Arkadiusz Bonna; Grazyna Faure; Tomasz Fraczyk; Ariel Roldan; Brice Hoffmann; Mélanie Faria da Cunha; Harald Herrmann; Gergely L Lukacs; Aleksander Edelman; Michał Dadlez
Journal:  Protein Sci       Date:  2017-02       Impact factor: 6.725

4.  Resveratrol rescues cAMP-dependent anionic transport in the cystic fibrosis pancreatic cell line CFPAC1.

Authors:  Nabila Hamdaoui; Maryvonne Baudoin-Legros; Mairead Kelly; Abdel Aissat; Sandra Moriceau; Diane-Lore Vieu; Julien Colas; Janine Fritsch; Aleksander Edelman; Gabrielle Planelles
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 5.  Applications of proteomic technologies for understanding the premature proteolysis of CFTR.

Authors:  Mark J Henderson; Om V Singh; Pamela L Zeitlin
Journal:  Expert Rev Proteomics       Date:  2010-08       Impact factor: 3.940

6.  Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients.

Authors:  Mario Ollero; Giuseppe Astarita; Ida Chiara Guerrera; Isabelle Sermet-Gaudelus; Stéphanie Trudel; Daniele Piomelli; Aleksander Edelman
Journal:  J Lipid Res       Date:  2011-02-18       Impact factor: 5.922

7.  Meta-GWAS Reveals Novel Genetic Variants Associated with Urinary Excretion of Uromodulin.

Authors:  Christina B Joseph; Marta Mariniello; Ayumi Yoshifuji; Guglielmo Schiano; Jennifer Lake; Jonathan Marten; Anne Richmond; Jennifer E Huffman; Archie Campbell; Sarah E Harris; Stephan Troyanov; Massimiliano Cocca; Antonietta Robino; Sébastien Thériault; Kai-Uwe Eckardt; Matthias Wuttke; Yurong Cheng; Tanguy Corre; Ivana Kolcic; Corrinda Black; Vanessa Bruat; Maria Pina Concas; Cinzia Sala; Stefanie Aeschbacher; Franz Schaefer; Sven Bergmann; Harry Campbell; Matthias Olden; Ozren Polasek; David J Porteous; Ian J Deary; Francois Madore; Philip Awadalla; Giorgia Girotto; Sheila Ulivi; David Conen; Elke Wuehl; Eric Olinger; James F Wilson; Murielle Bochud; Anna Köttgen; Caroline Hayward; Olivier Devuyst
Journal:  J Am Soc Nephrol       Date:  2022-03       Impact factor: 10.121

8.  Keratin K18 increases cystic fibrosis transmembrane conductance regulator (CFTR) surface expression by binding to its C-terminal hydrophobic patch.

Authors:  Yuanyuan Duan; Ying Sun; Fan Zhang; Wei Kevin Zhang; Dong Wang; Yan Wang; Xu Cao; Wenbao Hu; Changyan Xie; John Cuppoletti; Thomas M Magin; Haixia Wang; Zhenguo Wu; Ning Li; Pingbo Huang
Journal:  J Biol Chem       Date:  2012-10-08       Impact factor: 5.157

9.  An association study on contrasting cystic fibrosis endophenotypes recognizes KRT8 but not KRT18 as a modifier of cystic fibrosis disease severity and CFTR mediated residual chloride secretion.

Authors:  Frauke Stanke; Silke Hedtfeld; Tim Becker; Burkhard Tümmler
Journal:  BMC Med Genet       Date:  2011-05-06       Impact factor: 2.103

10.  A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients.

Authors:  Ida Chiara Guerrera; Giuseppe Astarita; Jean-Philippe Jais; Dorota Sands; Anna Nowakowska; Julien Colas; Isabelle Sermet-Gaudelus; Martin Schuerenberg; Daniele Piomelli; Aleksander Edelman; Mario Ollero
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.